From Earlier: FDA Grants TearLab Osmolarity System CLIA Waiver Categorization

TearLab Corporation (Nasdaq: TEAR) announced today that it is in receiptof a communication from the U.S. Food and Drug Administrationindicating that, based on a supervisory review of the Company's appeal, theAgency has granted its petition for a waiver under CLlA for the TearLabOsmolarity System. Upon the Company's submission of labeling acceptable to theAgency, the CLIA waiver will be issued.